Latest external collaboration on country level. Dive into details by clicking on the dots.
Dive into the research topics where Simona Barlera is active.
Featured researches published by Simona Barlera.
Circulation | 2007
Roberto Latini; Serge Masson; Inder S. Anand; Emil Missov; Marjorie Carlson; Tarcisio Vago; Laura Angelici; Simona Barlera; Giovanni Parrinello; Aldo P. Maggioni; Gianni Tognoni; Jay N. Cohn
Background— Circulating cardiac troponin T, a marker of cardiomyocyte injury, predicts adverse outcome in patients with heart failure (HF) but is detectable in only a small fraction of those with chronic stable HF. We assessed the prognostic value of circulating cardiac troponin T in patients with stable chronic HF with a traditional (cTnT) and a new precommercial highly sensitive assay (hsTnT). Methods and Results— Plasma troponin T was measured in 4053 patients with chronic HF enrolled in the Valsartan Heart Failure Trial (Val-HeFT). Troponin T was detectable in 10.4% of the population with the cTnT assay (detection limit ≤0.01 ng/mL) compared with 92.0% with the new hsTnT assay (≤0.001 ng/mL). Patients with cTnT elevation or with hsTnT above the median (0.012 ng/mL) had more severe HF and worse outcome. In Cox proportional hazards models adjusting for clinical risk factors, cTnT was associated with death (780 events; hazard ratio=2.08; 95% confidence interval, 1.72 to 2.52; P<0.0001) and first hospitalization for HF (655 events; hazard ratio=1.55; 95% confidence interval, 1.25 to 1.93; P<0.0001). HsTnT was associated with the risk of death in unadjusted analysis for deciles of concentrations and in multivariable models (hazard ratio=1.05; 95% confidence interval, 1.04 to 1.07 for increments of 0.01 ng/mL; P<0.0001). Addition of hsTnT to well-calibrated models adjusted for clinical risk factors, with or without brain natriuretic peptide, significantly improved prognostic discrimination (C-index, P<0.0001 for both outcomes). Conclusions— In this large population of patients with HF, detectable cTnT predicts adverse outcomes in chronic HF. By the highly sensitive assay, troponin T retains a prognostic value at previously undetectable concentrations.
The New England Journal of Medicine | 2013
Maria Carla Roncaglioni; Fausto Avanzini; Simona Barlera; Irene Marzona; Valentina Milani; Massimo Tombesi; Vittorio Caimi; Paolo Longoni; Maria Giuseppina Silletta; Gianni Tognoni; Roberto Marchioli
BACKGROUND Trials have shown a beneficial effect of n-3 polyunsaturated fatty acids in patients with a previous myocardial infarction or heart failure. We evaluated the potential benefit of such therapy in patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who had not had a myocardial infarction. METHODS In this double-blind, placebo-controlled clinical trial, we enrolled a cohort of patients who were followed by a network of 860 general practitioners in Italy. Eligible patients were men and women with multiple cardiovascular risk factors or atherosclerotic vascular disease but not myocardial infarction. Patients were randomly assigned to n-3 fatty acids (1 g daily) or placebo (olive oil). The initially specified primary end point was the cumulative rate of death, nonfatal myocardial infarction, and nonfatal stroke. At 1 year, after the event rate was found to be lower than anticipated, the primary end point was revised as time to death from cardiovascular causes or admission to the hospital for cardiovascular causes. RESULTS Of the 12,513 patients enrolled, 6244 were randomly assigned to n-3 fatty acids and 6269 to placebo. With a median of 5 years of follow-up, the primary end point occurred in 1478 of 12,505 patients included in the analysis (11.8%), of whom 733 of 6239 (11.7%) had received n-3 fatty acids and 745 of 6266 (11.9%) had received placebo (adjusted hazard ratio with n-3 fatty acids, 0.97; 95% confidence interval, 0.88 to 1.08; P=0.58). The same null results were observed for all the secondary end points. CONCLUSIONS In a large general-practice cohort of patients with multiple cardiovascular risk factors, daily treatment with n-3 fatty acids did not reduce cardiovascular mortality and morbidity. (Funded by Società Prodotti Antibiotici and others; ClinicalTrials.gov number, NCT00317707.).
Journal of the American College of Cardiology | 2008
Serge Masson; Roberto Latini; Inder S. Anand; Simona Barlera; Laura Angelici; Tarcisio Vago; Gianni Tognoni; Jay N. Cohn
OBJECTIVES This study sought to evaluate the association between changes over time of N-terminal pro-brain natriuretic peptide (NT-proBNP) expressed in different ways and outcome in patients with stable and chronic heart failure (HF). BACKGROUND Although previous studies examined the prognostic value of repeated determinations of BNP in HF, there are only limited data on the clinical utility of serial measurements of the inactive peptide NT-proBNP in a large population of ambulatory patients with chronic HF with sufficient follow-up time. METHODS The NT-proBNP was measured at randomization and after 4 months in 1,742 patients enrolled in the placebo arm of Val-HeFT (Valsartan Heart Failure Trial). Changes in NT-proBNP concentrations over 4 months were expressed as absolute change from baseline, percent relative changes, or categorical changes across a threshold value and related to subsequent mortality. RESULTS A single determination of NT-proBNP (area under the curve at 4 months: 0.702, 95% confidence interval [CI]: 0.669 to 0.735) showed a higher prognostic discrimination than continuous changes of concentrations, expressed either as absolute (0.592, 95% CI: 0.549 to 0.634) or relative changes (0.602, 95% CI: 0.566 to 0.639). A Cox proportional hazards model showed that stratification of patients into 4 categories according to NT-proBNP levels at 2 time points 4 months apart with respect to a threshold concentration provided prognostic information in patients with chronic HF beyond that of a single determination. CONCLUSIONS Serial determinations of NT-proBNP concentration and classification into few categories of changes according to threshold levels may be a superior strategy for risk stratification of patients with chronic and stable HF.
Journal of the American College of Cardiology | 2002
Maylene Wong; Lidia Staszewsky; Roberto Latini; Simona Barlera; Alberto Volpi; Yann Tong Chiang; Raymond L. Benza; Sidney O. Gottlieb; Thomas D. Kleemann; Franco Rosconi; Pieter M. Vandervoort; Jay N. Cohn
OBJECTIVES The objective of the study was to evaluate the effect of an angiotensin receptor blocker on left ventricular (LV) structure and function when added to prescribed heart failure therapy. BACKGROUND The clinical benefit derived from heart failure therapy is attributed to the regression of LV remodeling. METHODS At 302 multinational sites, 5,010 patients in New York Heart Association (NYHA) classification II to IV heart failure taking angiotensin-converting enzyme inhibitor (ACEI) and/or beta-blocker (BB) were randomized into valsartan and placebo groups and followed for a mean of 22.4 months. Serial echocardiographic measurements of left ventricular internal diastolic diameter (LVIDd) and ejection fraction (EF) were recorded. Total study reproducibility calculated to 90% power at 5% significance defined detectable differences of 0.09 cm for LVIDd and 0.86% for EF. RESULTS Baseline LVIDd and EF for valsartan and placebo groups were similar: 3.6 +/- 0.5 versus 3.7 +/- 0.5 (cm/m(2)) and 26.6 +/- 7.3 versus 26.9 +/- 7.0 (%). Mean group changes from baseline over time were compared. Significant decrease in LVIDd and increase in EF began by four months, reached plateau by one year, and persisted to two years in valsartan compared with placebo patients, irrespective of age, gender, race, etiology, NYHA classification, and co-treatment therapy. Changes at 18 months were -0.12 +/- 0.4 versus -0.05 +/- 0.4 (cm/m(2)), p < 0.00001 for LVIDd, and +4.5 +/- 8.9 versus +3.2 +/- 8.6 (%), p < 0.00001 for EF. The exception occurred in patients taking both ACEI and BB as co-treatment, in whom the decrease in LVIDd and increase in EF were no different between valsartan and placebo groups. CONCLUSIONS The Val-HeFT echocardiographic substudy of 5,010 patients with moderate heart failure demonstrated that valsartan therapy taken with either ACEI or BB reversed LV remodeling.
Nature Genetics | 2012
Elizabeth G. Holliday; Jane Maguire; Tiffany-Jane Evans; Simon A. Koblar; Jim Jannes; Jonathan Sturm; Graeme J. Hankey; Ross Baker; Jonathan Golledge; Mark W. Parsons; Rainer Malik; Mark McEvoy; Erik Biros; Martin D. Lewis; Lisa F. Lincz; Roseanne Peel; Christopher Oldmeadow; Wayne Smith; Pablo Moscato; Simona Barlera; Steve Bevan; Joshua C. Bis; Eric Boerwinkle; Giorgio B. Boncoraglio; Thomas G. Brott; Robert D. Brown; Yu-Ching Cheng; John W. Cole; Ioana Cotlarciuc; William J. Devan
Genome-wide association studies (GWAS) have not consistently detected replicable genetic risk factors for ischemic stroke, potentially due to etiological heterogeneity of this trait. We performed GWAS of ischemic stroke and a major ischemic stroke subtype (large artery atherosclerosis, LAA) using 1,162 ischemic stroke cases (including 421 LAA cases) and 1,244 population controls from Australia. Evidence for a genetic influence on ischemic stroke risk was detected, but this influence was higher and more significant for the LAA subtype. We identified a new LAA susceptibility locus on chromosome 6p21.1 (rs556621: odds ratio (OR) = 1.62, P = 3.9 × 10−8) and replicated this association in 1,715 LAA cases and 52,695 population controls from 10 independent population cohorts (meta-analysis replication OR = 1.15, P = 3.9 × 10−4; discovery and replication combined OR = 1.21, P = 4.7 × 10−8). This study identifies a genetic risk locus for LAA and shows how analyzing etiological subtypes may better identify genetic risk alleles for ischemic stroke.
Atherosclerosis | 2003
Benedetta D. Chiodini; Simona Barlera; Maria Grazia Franzosi; Violeta Labarta Beceiro; Martino Introna; Gianni Tognoni
BACKGROUND The APO B gene is characterised by numerous polymorphic sites, three of which (XbaI, EcoRI, SpIns/Del) are related to levels of total cholesterol (TC), low-density lipoproteins, apo B and tryglicerides, and to coronary artery disease (CAD) and/or myocardial infarction (MI). Moreover, conflicting results emerge from literature. To assess how each polymorphism of the APO B gene was associated with CAD and MI risk, we carried out a meta-analysis of all published studies. METHODS AND RESULTS Thirty case-control studies were considered, for a total of 6077, 3870 and 11616 individuals, respectively, for XbaI, EcoRI and SpIns/Del polymorphisms. For each polymorphism we calculated the risk of CAD/MI on the overall sample and for large and small studies separately. No evidence of increased risk emerged for XbaI polymorphism. Whereas, positive associations were detected for EcoRI, SpIns/Del and risk of CAD and MI, with odds ratio (OR) of 1.73 (95% CI, 1.19-2.50) and 1.19 (95% CI, 1.05-1.35) for carriers of AA and DD, respectively. CONCLUSIONS Despite the small size of most studies and the incomplete understanding of the effects of these polymorphisms on lipid metabolism and on final clinical implications, the findings suggest that EcoRI and SpIns/Del polymorphisms significantly increase the risk of CAD and MI. Despite the rarity of the allelic variant of EcoRI polymorphism, its presence is strongly related to the occurrence of CAD/MI. Moreover, there is a high consistency between small and large studies. The results on SpIns/Del polymorphism seem the most interesting and reliable, considering both the number of subjects analysed and the consistency of the evidence of its effect on lipid levels. These results need to be confirmed by larger and appropriately powered studies.
European Journal of Heart Failure | 2007
Mariantonietta Cicoira; Aldo P. Maggioni; Roberto Latini; Simona Barlera; Elisa Carretta; Andras Janosi; Jordi Soler Soler; Inder S. Anand; Jay N. Cohn
To assess the relationship between body mass index (BMI), mortality and mode of death in chronic heart failure (CHF) patients; to define the shape of the relationship between BMI and mortality.
The New England Journal of Medicine | 2017
Li Shen; Pardeep S. Jhund; Mark C. Petrie; Brian Claggett; Simona Barlera; John G.F. Cleland; Henry Dargie; Christopher B. Granger; John Kjekshus; Lars Køber; Roberto Latini; Aldo P. Maggioni; Milton Packer; Bertram Pitt; Scott D. Solomon; Karl Swedberg; Luigi Tavazzi; John Wikstrand; Faiez Zannad; Michael R. Zile; John J.V. McMurray
Background The risk of sudden death has changed over time among patients with symptomatic heart failure and reduced ejection fraction with the sequential introduction of medications including angiotensin‐converting–enzyme inhibitors, angiotensin‐receptor blockers, beta‐blockers, and mineralocorticoid‐receptor antagonists. We sought to examine this trend in detail. Methods We analyzed data from 40,195 patients who had heart failure with reduced ejection fraction and were enrolled in any of 12 clinical trials spanning the period from 1995 through 2014. Patients who had an implantable cardioverter–defibrillator at the time of trial enrollment were excluded. Weighted multivariable regression was used to examine trends in rates of sudden death over time. Adjusted hazard ratios for sudden death in each trial group were calculated with the use of Cox regression models. The cumulative incidence rates of sudden death were assessed at different time points after randomization and according to the length of time between the diagnosis of heart failure and randomization. Results Sudden death was reported in 3583 patients. Such patients were older and were more often male, with an ischemic cause of heart failure and worse cardiac function, than those in whom sudden death did not occur. There was a 44% decline in the rate of sudden death across the trials (P=0.03). The cumulative incidence of sudden death at 90 days after randomization was 2.4% in the earliest trial and 1.0% in the most recent trial. The rate of sudden death was not higher among patients with a recent diagnosis of heart failure than among those with a longer‐standing diagnosis. Conclusions Rates of sudden death declined substantially over time among ambulatory patients with heart failure with reduced ejection fraction who were enrolled in clinical trials, a finding that is consistent with a cumulative benefit of evidence‐based medications on this cause of death. (Funded by the China Scholarship Council and the University of Glasgow.)
Circulation-heart Failure | 2013
Simona Barlera; Luigi Tavazzi; Maria Grazia Franzosi; Roberto Marchioli; Elena Raimondi; Serge Masson; Renato Urso; Donata Lucci; Gian Luigi Nicolosi; Aldo P. Maggioni; Gianni Tognoni
Background —We developed a prognostic model to assess the risk of all-cause mortality in patients with chronic heart failure (HF). Methods and Results —We examined 6975 patients with chronic HF enrolled in the GISSI-HF trial (3.9 years follow-up). Multi-variable Cox regression models were developed to predict mortality (1969 deaths). By stepwise selection, the full final model included 25 predictors. A reduced model, considering the most significant variables ranked according to the Wald Chi-Square (p <0.0001) accounted for most of the prognostic information. Internal validation of the model was performed with bootstrap techniques. The discrimination ability of the reduced model constituted by 12 factors (CPE=0.693) was as good as the full final model (CPE= 0.70). Among the first 12 independent risk factors emerging in the reduced model, the three most powerful predictors were older age, higher NYHA class and lower estimated glomerular filtration rate (eGFR). Other independent predictors that increased risk included lower left ventricular ejection fraction, chronic obstructive pulmonary disease, lower systolic blood pressure, diabetes, male sex, higher uricemia, lower body mass index, lower hemoglobin and aortic stenosis. The reduced model was used to build a nomogram to estimate the risk of death in individual patients. In a subgroup of patients, the two well-known biomarkers (hs-cTnT and NT-proBNP) emerged as the most powerful predictors of outcome. Conclusions —In a large contemporary chronic HF population, this model offers good ability to assess the risk of death, confirming most of the risk factors that have emerged in recent trials. Clinical Trial Registration —URL: http://www.clinicaltrials.gov. Unique identifier: [NCT00336336]. : /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00336336&atom=%2Fcirchf%2Fearly%2F2012%2F11%2F14%2FCIRCHEARTFAILURE.112.967828.atom
European Journal of Heart Failure | 2007
Jawdat Abdulla; Simona Barlera; Roberto Latini; Lars Kjøller-Hansen; Peter Søgaard; Erik Christensen; Lars Køber; Christian Torp-Pedersen
To summarize and quantify results of echocardiographic studies examining the effect of angiotensin converting enzyme (ACE) inhibition on left ventricular remodelling in patients with acute myocardial infarction (MI) and in patients with left ventricular systolic dysfunction (LVSD).